In summary, our findings reveal USP39 promotes malignant phenotypes of ESCC cells as a splicing factor and identify USP39 as a new biomarker of poor prognosis and a candidate therapeutic target in ESCC. Here, SLU7 is linked to esophageal squamous cell carcinoma.